RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

06 Dec 2021 08:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

15 Nov 2021 07:45:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

09 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results

02 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

01 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

20 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

14 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

14 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program

14 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

22 Sep 2021 10:30:00 By Nasdaq GlobeNewswire